Medivir Plans For A Post-Simeprevir Future

The hepatitis C therapy simeprevir may have been a commercial success for the small Swedish biotech Medivir, but as competition increases and sales decline, the company is planning for what comes next.

The board of Medivir AB says it wants to complete the division of the company into two publicly listed companies by the end of 2016, as the Swedish biotech continues to work on a strategy to cope with declining royalties from its hepatitis C protease inhibitor, simeprevir.

A separate listing of a so-far unnamed commercial company on First North Premium, NASDAQ’s European market of smaller by fast-growing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip